691 related articles for article (PubMed ID: 25662515)
1. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Apr; 94():9-25. PubMed ID: 25662515
[TBL] [Abstract][Full Text] [Related]
2. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
3. Src protein-tyrosine kinase structure and regulation.
Roskoski R
Biochem Biophys Res Commun; 2004 Nov; 324(4):1155-64. PubMed ID: 15504335
[TBL] [Abstract][Full Text] [Related]
4. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
5. The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions.
Williams JC; Weijland A; Gonfloni S; Thompson A; Courtneidge SA; Superti-Furga G; Wierenga RK
J Mol Biol; 1997 Dec; 274(5):757-75. PubMed ID: 9405157
[TBL] [Abstract][Full Text] [Related]
6. Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases.
Chong YP; Ia KK; Mulhern TD; Cheng HC
Biochim Biophys Acta; 2005 Dec; 1754(1-2):210-20. PubMed ID: 16198159
[TBL] [Abstract][Full Text] [Related]
7. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes.
Roskoski R
Pharmacol Res; 2016 Jan; 103():26-48. PubMed ID: 26529477
[TBL] [Abstract][Full Text] [Related]
8. C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK)--endogenous negative regulators of Src-family protein kinases.
Chong YP; Mulhern TD; Cheng HC
Growth Factors; 2005 Sep; 23(3):233-44. PubMed ID: 16243715
[TBL] [Abstract][Full Text] [Related]
9. Novel mechanism of regulation of the non-receptor protein tyrosine kinase Csk: insights from NMR mapping studies and site-directed mutagenesis.
Shekhtman A; Ghose R; Wang D; Cole PA; Cowburn D
J Mol Biol; 2001 Nov; 314(1):129-38. PubMed ID: 11724538
[TBL] [Abstract][Full Text] [Related]
10. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
11. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
Roskoski R
Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
[TBL] [Abstract][Full Text] [Related]
12. Csk-homologous kinase (Chk) is an efficient inhibitor of Src-family kinases but a poor catalyst of phosphorylation of their C-terminal regulatory tyrosine.
Advani G; Lim YC; Catimel B; Lio DSS; Ng NLY; Chüeh AC; Tran M; Anasir MI; Verkade H; Zhu HJ; Turk BE; Smithgall TE; Ang CS; Griffin M; Cheng HC
Cell Commun Signal; 2017 Aug; 15(1):29. PubMed ID: 28784162
[TBL] [Abstract][Full Text] [Related]
13. Properties of FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
[TBL] [Abstract][Full Text] [Related]
14. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
16. SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo.
Lerner EC; Smithgall TE
Nat Struct Biol; 2002 May; 9(5):365-9. PubMed ID: 11976726
[TBL] [Abstract][Full Text] [Related]
17. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Mar; 129():65-83. PubMed ID: 29408302
[TBL] [Abstract][Full Text] [Related]
18. Structure of the regulatory domains of the Src-family tyrosine kinase Lck.
Eck MJ; Atwell SK; Shoelson SE; Harrison SC
Nature; 1994 Apr; 368(6473):764-9. PubMed ID: 7512222
[TBL] [Abstract][Full Text] [Related]
19. Purification of bovine thymus cytosolic C-terminal Src kinase (CSK) and demonstration of differential efficiencies of phosphorylation and inactivation of p56lyn and pp60c-src by CSK.
Cheng HC; Bjorge JD; Aebersold R; Fujita DJ; Wang JH
Biochemistry; 1996 Sep; 35(36):11874-87. PubMed ID: 8794770
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
Roskoski R
Pharmacol Res; 2016 Nov; 113(Pt A):395-408. PubMed ID: 27641927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
